Cingulate (NASDAQ:CING) Stock Breaks Above Fifty Day Moving Average - Time to Sell?

Key Points

• Cingulate shares rose 4%, trading at $5.18 after briefly reaching $5.27 and moving above the 50-day moving average of $5.02; the 200-day average remains higher at $5.43.
• Analyst sentiment is mixed but leans positive: three analysts rate the stock Buy and one rates it Sell, producing a consensus “Moderate Buy” rating and a $27 target price.
• The clinical-stage biotech exceeded quarterly EPS expectations, reporting a $0.45 loss versus the anticipated $0.63 loss, while institutional investors own 41.31% of the company.

Cingulate Inc. (NASDAQ:CING - Get Free Report)'s share price crossed above its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $5.02 and traded as high as $5.27. Cingulate shares last traded at $5.18, with a volume of 229,764 shares traded.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Weiss Ratings raised shares of Cingulate from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, October 20th. Roth Capital set a $9.00 price objective on shares of Cingulate and gave the company a "buy" rating in a report on Sunday, August 23rd. Finally, Wall Street Zen raised shares of Cingulate from a "sell" rating to a "hold" rating in a research report on Saturday, August 29th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $27.00.

Cingulate Stock Up 4.0%

The company has a 50-day moving average of $5.02 and a 200-day moving average of $5.43. The company has a market cap of $75.32 million, a PE ratio of -1.44 and a beta of -0.88.

Cingulate (NASDAQ:CING - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.45) EPS for the quarter, beating analysts' consensus estimates of ($0.63) by $0.18. As a group, equities analysts predict that Cingulate Inc. will post -2.19 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Kestra Advisory Services LLC increased its stake in Cingulate by 14.8% in the 1st quarter. Kestra Advisory Services LLC now owns 140,000 shares of the company's stock valued at $869,000 after buying an additional 18,000 shares during the last quarter. BlackRock Inc. purchased a new stake in shares of Cingulate during the second quarter valued at approximately $291,000. Renaissance Technologies LLC purchased a new stake in shares of Cingulate during the first quarter valued at approximately $198,000. Finally, Chicago Partners Investment Group LLC purchased a new stake in shares of Cingulate during the first quarter valued at approximately $116,000. 41.31% of the stock is owned by institutional investors.

About Cingulate

Cingulate Inc NASDAQ: CING is a clinical-stage biopharmaceutical company focused on developing treatments for attention-deficit/hyperactivity disorder (ADHD) and other central nervous system conditions. The company's lead programs are based on its proprietary Precision Timed Release (PTR) drug-delivery platform, which is designed to provide controlled, timed releases of medication from a single oral dose.

Cingulate's primary product candidate is CTx-1301, an extended-release formulation of dexmethylphenidate intended to provide all-day ADHD symptom control through multiple releases of the active ingredient.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.